Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics - Wikidata - awgldk - TriplyDB

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics

http://www.wikidata.org/entity/Q24811190

about

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia Sulpiride augmentation for schizophrenia Sulpiride augmentation for schizophrenia Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia Development of a Web-Based Clinical Decision Support System for Drug Prescription: Non-Interventional Naturalistic Description of the Antipsychotic Prescription Patterns in 4345 Outpatients and Future Applications A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy Improvement and decline of cognitive function in schizophrenia over one year: a longitudinal investigation using latent growth modelling.Cost of antipsychotic polypharmacy in the treatment of schizophrenia.Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis.Antipsychotic polypharmacy in a regional health service: a population-based study.Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder.Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials.Polypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems.Validation of a claims-based antipsychotic polypharmacy measure The 3-year clinical and functional course of schizophrenia among individuals with and without diabetes at study entry The burden of depressive symptoms in the long-term treatment of patients with schizophrenia.Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems.Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis Prevalence of Antipsychotic Polypharmacy and Associated Factors among Outpatients with Schizophrenia Attending Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia.Antipsychotics prescribing patterns of patients with schizophrenia admitted to korean general hospital psychiatric unit: 2001 to 2008.Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice Predictors of long-term (≥6months) antipsychotic polypharmacy prescribing in secondary mental healthcare.Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials.Antipsychotic polypharmacy: a Japanese survey of prescribers' attitudes and rationales.Does antipsychotic polypharmacy increase the risk for metabolic syndrome?Polypharmacy in the management of patients with schizophrenia on risperidone in a tertiary-care hospital in Malaysia Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia.Prescription Drug Use and Polypharmacy Among Medicaid-Enrolled Adults with Autism: A Retrospective Cross-Sectional Analysis Do doctors agree on doses of antipsychotic medications?Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis Antipsychotic polypharmacy in schizophrenia: benefits and risks.Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials.Comparison of treatment patterns in schizophrenia between China and Japan (2001-2009).Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports.

P2860

Q21260279-D1E7DF6A-AEED-47C5-A463-1ED066D98CFA Q24240818-3F04391D-E79A-4DDF-B53B-6CA3BDF5003E Q24241371-B0D40101-E53A-4301-A833-69E36C64F591 Q27028197-5857A45F-18F3-4295-A70F-877834534FFB Q28248687-4E0F4C96-8C64-4100-A9B6-74352650BDCE Q28552825-A55AB307-5A82-42EC-B1E5-A47CB1C2ECB4 Q30485065-BD88C45E-81C6-4DBE-8DE4-953204CB574C Q33284145-C441A70E-EB43-46E4-806E-123A9901914E Q33327172-769EC504-7CA4-47A0-9FF5-0594449EED09 Q33399275-AC088ACE-8A0D-4701-9E2F-053DFC06310D Q33488323-BA5848C7-FA13-4268-B053-1688882297A1 Q33818732-03BE6642-F849-433C-9943-688B8FE5F40C Q34269517-EE549202-C3CD-4248-A9DA-9343B4AB4008 Q34603527-6955745A-2B43-4C45-A842-5E88E966518A Q34686544-4C12C05E-95E9-4DEB-9A5C-1CCF2551D508 Q35175610-E3C7522C-B54C-4EF7-9B61-2C165C2B68D9 Q35256929-674330B1-C917-466A-B7A3-A605EFBB37B5 Q35608522-5830975E-F3E7-428A-9A6C-25F180F005F0 Q35801221-6C03DB67-64EE-47B8-94A3-C75E5E40C127 Q35851083-132DD59B-30E6-4D13-87BB-B443F443A4E1 Q35921541-216A1918-37DC-417C-B66D-BA09BB3C73AC Q36024341-65EE14EA-781C-449B-8567-7F368042EDFF Q36057820-483F812D-0B93-49D7-80B0-1F15D07C909A Q36065092-5B6AFD45-8C45-49C5-8D96-746D8DCFD22C Q36556487-FD6716EE-28EF-4D8D-8B03-475C6CDF8FAE Q36599207-E72CE038-5EFC-4FBE-B1BF-8BF799BD9A33 Q37029622-92070BF6-ECCA-4AA4-AA24-66D13A07FE2A Q37042072-62DB8AC9-4B69-4D4D-B728-44776FCCA04C Q37137001-7F82740D-8C7A-4D8E-BD80-9F4A81E08328 Q37216848-5092B8B2-F3C0-45EE-B3E0-A4ACE4A0D466 Q37281587-D5D2A0F1-650A-4EB9-AF47-08F305E6059E Q37294192-6E588525-7009-4DCC-8C8D-27A60729C7D4 Q37405519-ACF295FC-A336-4D67-B7FC-D3862E7650EB Q37452761-9266A7AB-0C94-4534-AE37-96257E6DFF3E Q37514630-3CC4AF13-D60F-4B88-A88C-05F05D1FE590 Q37609168-AB7E6355-8D70-4060-9489-1207338F6E70 Q37863093-F014C973-90CA-4472-B7B0-135E8E86600A Q38769838-5852F835-9619-47DF-B866-BA9160E83A83 Q38950803-E7BE5F2B-C7AE-421E-BB03-F7BA9465A722 Q40050322-0B5BAADB-F77B-4B74-958E-22C4E66C559C

P2860

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics

http://www.wikidata.org/entity/Q24811190

description

2005 nî lūn-bûn

@nan

2005 թուականին հրատարակուած գիտական յօդուած

@hyw

2005 թվականին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Antipsychotic monotherapy and ...... a with atypical antipsychotics

@ast

Antipsychotic monotherapy and ...... a with atypical antipsychotics

@en

Antipsychotic monotherapy and ...... a with atypical antipsychotics

@nl

type

label

Antipsychotic monotherapy and ...... a with atypical antipsychotics

@ast

Antipsychotic monotherapy and ...... a with atypical antipsychotics

@en

Antipsychotic monotherapy and ...... a with atypical antipsychotics

@nl

prefLabel

Antipsychotic monotherapy and ...... a with atypical antipsychotics

@ast

Antipsychotic monotherapy and ...... a with atypical antipsychotics

@en

Antipsychotic monotherapy and ...... a with atypical antipsychotics

@nl

P1433

Q24811190-DC29FDE7-4C29-4DEF-81DF-B0D12E606B9B

P1476

Q24811190-133856D3-7533-4A18-B236-FFA66196E520

P2093

Q24811190-15C505F0-94A3-4DFB-89C1-7FAAC0505C3A

Q24811190-4E616912-987A-4BD2-851D-50A7186EF92E

Q24811190-5D38F1D4-17CD-4F04-8A5A-E9AC9CA897CC

Q24811190-86068054-B147-41AD-81FA-91AE6F86BAC1

P2860

Q24811190-002C2860-5464-487A-9BCE-4E7CD6027935

Q24811190-0C7BB100-C18F-4E5B-A88D-ABB5F57DA6B3

Q24811190-13B4ACEE-7221-4603-BAE2-53941980F597

Q24811190-216BC41E-9464-4C9C-9016-8E50CC559623

Q24811190-2842906D-D7FD-4853-8E2C-E51CAC3423F4

Q24811190-2BFF3186-8234-42AB-BBCA-AD406C518EED

Q24811190-364E837B-A284-47E5-9D58-2A4E0AE90341

Q24811190-506CABC5-7BCD-427F-A5D5-EC289429578C

Q24811190-537DA6CA-1879-4C52-A717-E652A125005C

Q24811190-5F7C6BF2-CE80-472D-9C7D-CA2BC68C269E

P2888

Q24811190-7ABAC5A3-53E4-4E88-8375-588B1F63097F

P304

Q24811190-DEDDC68C-91E8-4708-B56F-390F4C746361

P31

Q24811190-8585711B-4576-4F39-8CA9-A108803B5BFD

P3181

Q24811190-70E7BB20-EAA2-4412-B635-0A18C84B270B

P356

Q24811190-88201FFD-3349-4D0C-90E4-26FA6DA0765F

P407

Q24811190-5AC903FE-640F-4AD4-BC9C-0D4213EA3D37

P433

Q24811190-202CD635-3E73-4592-B05E-444C8E9C2AD8

P478

Q24811190-969C0FB7-1FDC-4718-A948-0F029E677C4A

P50

Q24811190-5883029C-3062-4734-88C9-E9E4EA2247B5

P577

Q24811190-CE3DAF05-2B52-4E07-BBB1-22CC969388FB

P5875

Q24811190-1029DB74-20B9-40D1-962C-192E6C953368

P6179

Q24811190-37BA6F16-5EE7-4A73-8F80-4819CCBAA491

P698

Q24811190-D8FC9864-4880-459B-8784-1FDBDA6908CB

P921

Q24811190-496ADD73-351A-4577-9DA8-302BA726C11D

P932

Q24811190-11F00F09-1E90-48C1-8EAE-D413F3650A90

P3181

P356

P1433

P1476

Antipsychotic monotherapy and ...... a with atypical antipsychotics

@en

P2093

Baojin Zhu

http://www.w3.org/2001/XMLSchema#string

Christoph Correll

http://www.w3.org/2001/XMLSchema#string

Douglas Faries

http://www.w3.org/2001/XMLSchema#string

John Kane

http://www.w3.org/2001/XMLSchema#string

P2860

A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia

Algorithm for treatment-refractory schizophrenia.

Practice guideline for the treatment of patients with schizophrenia, second edition.

Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations.

Antipsychotic medication coprescribing in a large state hospital system.

Dose response and dose equivalence of antipsychotics.

The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003.

Antipsychotic prescribing practices in the Veterans Healthcare Administration--New York metropolitan region.

Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.

Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.

P2888

P304

26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2282716

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/1471-244X-5-26

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Haya Ascher-Svanum

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7819391

http://www.w3.org/2001/XMLSchema#string

P6179

1042409635

http://www.w3.org/2001/XMLSchema#string

P698

15921508

http://www.w3.org/2001/XMLSchema#string

P921

P932

1156914

http://www.w3.org/2001/XMLSchema#string